Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study

• Published in: International immunopharmacology Vol. 130; p. 111706
• Main Authors: Ye, Young-Min, Park, Jung-Won, Kim, Sae-Hoon, Cho, You Sook, Lee, Sook Young, Lee, Sae Young, Sim, Sujin, Song, Eunji, Kim, Bomin, Lee, Jieon, Kim, Su Kyung, Jang, Myoung Ho, Park, Hae-Sim
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 30.03.2024
• Subjects: (6 max): Atopy; Allergy; anti-IgE antibody; IgE; Mast cell; Allergy; Mast cell; anti-IgE antibody; IgE; (6 max): Atopy

•Treatment-emergent adverse events (TEAEs) were mainly grade 1 or 2.•No serious AEs, treatment discontinuation due to AEs, or anaphylaxis were reported.•YH35324 (0.3–9 mg/kg) showed a dose-proportional increase in Cmax and AUClast.•Serum-free IgE level was rapidly suppressed to a significant extent...